Avidity Partners Management Lp
- Regulatory AUM
- $1.1B
- Discretionary
- $1.1B
- Clients
- 7
- Avg AUM / client
- $151M
- Accounts
- 7
- Employees
- 9
AUM over time
Annual snapshots from Form ADV filings · as of Mar 31, 2026
Investments (13F portfolio — 45 positions, $493,809,335)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Dianthus Therapeutics Inc | COM | $176,583,121 | 2,104,184 | 35.8% | 16.7% |
| 2 | Cg Oncology Inc | COM | $87,236,001 | 1,288,948 | 17.7% | 8.24% |
| 3 | Oruka Therapeutics Inc | COM | $37,298,797 | 760,424 | 7.55% | 3.52% |
| 4 | Perspective Therapeutics Inc | COM NEW | $25,228,496 | 6,049,999 | 5.11% | 2.38% |
| 5 | Jade Biosciences Inc | COM NEW | $19,679,947 | 1,400,708 | 3.99% | 1.86% |
| 6 | Enliven Therapeutics Inc | COM | $15,680,000 | 400,000 | 3.18% | 1.48% |
| 7 | Teva Pharm Adr | COM | $13,557,012 | 450,100 | 2.75% | 1.28% |
| 8 | Context Therapeutics Inc | COM | $13,095,460 | 4,998,267 | 2.65% | 1.24% |
| 9 | Repligen Corp | COM | $9,166,396 | 77,800 | 1.86% | 0.87% |
| 10 | Palvella Therapeutics Inc | COM | $8,725,500 | 70,000 | 1.77% | 0.82% |
| 11 | Medtronic Inc | SHS | $8,665,000 | 100,000 | 1.75% | 0.82% |
| 12 | Vir Biotechnology Inc | COM | $8,512,000 | 950,000 | 1.72% | 0.8% |
| 13 | Aktis Oncology Inc | COM | $8,382,646 | 468,566 | 1.7% | 0.79% |
| 14 | Immunic Inc | COM | $7,436,346 | 6,699,411 | 1.51% | 0.7% |
| 15 | Dexcom | COM | $5,652,000 | 90,000 | 1.14% | 0.53% |
| 16 | Encompass Health Corp | COM | $4,062,660 | 42,000 | 0.82% | 0.38% |
| 17 | Boston Scientific Corporation | COM | $3,765,000 | 60,000 | 0.76% | 0.36% |
| 18 | Tenax Therapeutics Inc | COM NEW | $3,452,785 | 215,934 | 0.7% | 0.33% |
| 19 | Gilead Sciences Inc | COM | $2,787,400 | 20,000 | 0.56% | 0.26% |
| 20 | Phathom Pharmaceuticals Inc | COM | $2,770,723 | 249,390 | 0.56% | 0.26% |
| 21 | Karyopharm Therapeutics Inc | COM NEW | $2,583,037 | 463,741 | 0.52% | 0.24% |
| 22 | Centene Corp | COM | $2,291,800 | 70,000 | 0.46% | 0.22% |
| 23 | Satellos Bioscience Inc | COM | $2,183,139 | 387,769 | 0.44% | 0.21% |
| 24 | Scynexis Inc | COM NEW | $1,908,674 | 2,081,660 | 0.39% | 0.18% |
| 25 | Natera Inc | COM | $1,799,910 | 9,000 | 0.36% | 0.17% |
Top 25 of 45 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 7 | $1.1B | 100.0% |
Private funds (4)
Reported in Form ADV Section 7.B.(1), filing of Mar 2024 · $5.3B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Avidity Master Fund Lp master | Hedge Fund | Cayman Islands | $4.8B | 166 |
| Avidity Private Master Fund I Lp master | Hedge Fund | Cayman Islands | $412M | 18 |
| Avidity Capital Fund Ii Lp | Hedge Fund | Delaware | $38.4M | 10 |
| Avidity Master Fund Iii Lp master | Hedge Fund | Cayman Islands | $30.0M | 4 |
People (5)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Gandy, Jared, Allan | Chief Financial Officer | Apr 2019 (7y) | Less than 5% | |
| Gregory, Michael, David | Co Managing Partner, Director Of Research, President Of Business Operations | Apr 2019 (7y) | 25% – 50% | |
| Witzke, David, Roy | Co Managing Partner, Portfolio Manager, Chief Investment Officer | Apr 2019 (7y) | 25% – 50% | |
| So, Andrew, Chee Wai | General Counsel | May 2021 (5y) | Less than 5% | |
| Raibourn, Delmer, Dee | Chief Compliance Officer | Jul 2022 (4y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| Witzke Avidity Trust | Limited Partner | Oct 2019 | A | 10% – 25% |
| Gregory Avidity Trust | Limited Partner | Oct 2019 | A | 10% – 25% |
| Avidity Partners Management (Gp) Llc | General Partner | Apr 2019 | A | Less than 5% |
Undisclosed: 0% – 30% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (4, $5.3B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Avidity Master Fund Lp | Hedge Fund | $4.8B | $5.0M | 166 |
| Avidity Private Master Fund I Lp | Hedge Fund | $412M | $10.0M | 18 |
| Avidity Capital Fund Ii Lp | Hedge Fund | $38.4M | $5.0M | 10 |
| Avidity Master Fund Iii Lp | Hedge Fund | $30.0M | $5.0M | 4 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 1.73 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
No disciplinary events reported on the firm's latest Form ADV filing.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Firm reports it does not have custody of client funds or securities (Item 9.A).
No custodian data reported or mined yet.
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗